Single-Cell Analysis of Circulating Tumor Cells.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2019
Historique:
entrez: 17 1 2019
pubmed: 17 1 2019
medline: 25 6 2019
Statut: ppublish

Résumé

Circulating tumor cells (CTCs) are rare cells that can be found in the peripheral blood of cancer patients. They have been demonstrated to be useful prognostic markers in many cancer types. Within the last decade various methods have been developed to detect rare cells within a liquid biopsy from a cancer patient. These methods have revealed the phenotypic diversity of CTCs and how they can represent the complement of cells that are found in a tumor. Single-cell proteogenomics has emerged as an all-encompassing next-generation technological approach for CTC research. This allows for the deconstruction of cellular heterogeneity, dynamics of metastatic initiation and progression, and response or resistance to therapeutics in the clinical settings. We take advantage of this opportunity to investigate CTC heterogeneity and understand their full potential in precision medicine.The high-definition single-cell analysis (HD-SCA) workflow combines detection of the entire population of CTCs and rare cancer related cells with single-cell genomic analysis and may therefore provide insight into their subpopulations based on molecular as well as morphological data. In this chapter we describe in detail the protocols from isolation of a candidate cell from a microscopy slide, through whole-genome amplification and library preparation, to CNV analysis of identified cells from the HD-SCA workflow. This process may also be applicable to any platform starting with a standard microscopy slide or isolated cell of interest.

Identifiants

pubmed: 30649733
doi: 10.1007/978-1-4939-9004-7_17
pmc: PMC7679177
mid: NIHMS1621438
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-264

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States

Références

N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Int J Gynecol Cancer. 2011 Jul;21(5):822-30
pubmed: 21613958
Cancer Lett. 2013 Nov 1;340(2):284-95
pubmed: 23174106
Nature. 2007 Dec 20;450(7173):1235-9
pubmed: 18097410
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14608-13
pubmed: 11121063
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Phys Biol. 2015 Jan 09;12(1):016008
pubmed: 25574741
PLoS One. 2014 Aug 01;9(8):e101777
pubmed: 25084170
J Cell Biochem. 2018 Jun;119(6):4236-4240
pubmed: 28833502
Genome Res. 2009 Sep;19(9):1639-45
pubmed: 19541911
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 32670616
Cancer Res. 2013 May 1;73(9):2760-9
pubmed: 23447576
Nat Protoc. 2012 May 03;7(6):1024-41
pubmed: 22555242
Genome Res. 2015 May;25(5):714-24
pubmed: 25858951
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Recent Results Cancer Res. 2012;195:69-76
pubmed: 22527495
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):251-258
pubmed: 28374743
Cancer Treat Rev. 1975 Mar;2(1):55-72
pubmed: 1102085
Bioinformatics. 2007 Mar 15;23(6):657-63
pubmed: 17234643
Expert Rev Mol Diagn. 2014 Mar;14(2):131-4
pubmed: 24437950
Phys Biol. 2014 Feb;11(1):016002
pubmed: 24406475
Nature. 2016 Jan 21;529(7586):298-306
pubmed: 26791720
J Thorac Oncol. 2014 Aug;9(8):1111-9
pubmed: 25157764
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21083-8
pubmed: 24324171
Genome Med. 2011 May 31;3(5):31
pubmed: 21631906
J Cancer Res Clin Oncol. 2015 Jan;141(1):87-92
pubmed: 25108406
Acta Cytol. 1976 Mar-Apr;20(2):151-7
pubmed: 59501
Annu Rev Pathol. 2017 Jan 24;12:419-447
pubmed: 28135562
Phys Biol. 2012 Feb;9(1):016003
pubmed: 22306768
J Oncol. 2010;2010:617421
pubmed: 20016752

Auteurs

Jana- A Thiele (JA)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Pavel Pitule (P)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

James Hicks (J)

USC Michelson Center for Convergent Biosciences, CSI-Cancer, Department of Biological Sciences, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA.

Peter Kuhn (P)

USC Michelson Center for Convergent Biosciences, CSI-Cancer, Department of Biological Sciences, Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, USA. peter.kuhn@usc.edu.
Department of Biomedical Engineering and Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, USA. peter.kuhn@usc.edu.
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. peter.kuhn@usc.edu.
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. peter.kuhn@usc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH